Outlook Therapeutics Inc. shares are trading higher Tuesday after the FDA granted its appeal in the ONS-5010 dispute resolution process.
Outlook Therapeutics, Inc.
(NASDAQ:OTLK) shares are trading higher Tuesday after the company announced that the U.S.
Food and Drug Administration granted its appeal following the Formal Dispute Resolution process for ONS-5010 or LYTENAVA (bevacizumab-vikg).
Outlook stock is showing exceptional strength.
What's behind OTLK gains?
Outlook moves toward potential US nod for thrice-snubbed eye drug with FDA appeal win
Three CRLs later, Outlook says FDA will sign off on its version of Avastin for wet AMD
Immunovant shares surge on arthritis trial data
Amgen's Tavneos, facing liver injury scrutiny, gets label update in Japan as patient starts resume
After prior FDA manufacturing snub, Gilead's hepatitis D med Hepcludex nabs US nod
AstraZeneca, Daiichi beat Gilead to first-line TNBC with FDA nod for Datroway
EU and US advisers split over AstraZeneca breast cancer drug
Datroway nabs FDA approval for immunotherapy-ineligible triple-negative breast cancer
Outlook Therapeutics has notched a win in its uphill battle to commercialize an ophthalmic version of Roche’s Avastin…
Outlook Therapeutics said the agency has reversed course regarding its reformulated version of Avastin for the eye condition…
Trial results for Lilly's "triple-G" drug, FDA's leadership purge leaves chaos, and more biotech news from The Readout
The experimental drug reduced flare-ups for patients with chronic obstructive pulmonary disease, Astra said Friday.
Immunovant shares climbed on results an analyst deemed “compelling” in tough-to-treat arthritis. Elsewhere, Wave’s pioneering…
The companies developing Ebvallo reached an agreement with the FDA to address its main reason for rejecting the drug.
